$3.15 Million in Sales Expected for Unum Therapeutics Inc (UMRX) This Quarter
Brokerages expect Unum Therapeutics Inc (NASDAQ:UMRX) to report $3.15 million in sales for the current quarter, according to Zacks. Three analysts have made estimates for Unum Therapeutics’ earnings, with the lowest sales estimate coming in at $1.80 million and the highest estimate coming in at $4.41 million. Unum Therapeutics reported sales of $2.22 million during the same quarter last year, which would suggest a positive year over year growth rate of 41.9%. The business is scheduled to issue its next quarterly earnings report on Monday, May 13th.
On average, analysts expect that Unum Therapeutics will report full year sales of $13.96 million for the current fiscal year, with estimates ranging from $7.00 million to $17.62 million. For the next financial year, analysts anticipate that the business will post sales of $17.10 million, with estimates ranging from $9.00 million to $25.33 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Unum Therapeutics.
Unum Therapeutics (NASDAQ:UMRX) last announced its quarterly earnings results on Thursday, March 28th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04. The company had revenue of $3.80 million during the quarter, compared to analysts’ expectations of $2.58 million. Unum Therapeutics had a negative return on equity of 96.46% and a negative net margin of 354.88%.
In related news, insider Seth Ettenberg sold 11,485 shares of the company’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $4.12, for a total value of $47,318.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its stake in Unum Therapeutics by 2,782.4% in the third quarter. JPMorgan Chase & Co. now owns 20,753 shares of the company’s stock valued at $213,000 after buying an additional 20,033 shares during the last quarter. Citadel Advisors LLC purchased a new stake in Unum Therapeutics in the third quarter valued at about $235,000. Renaissance Technologies LLC purchased a new stake in Unum Therapeutics in the third quarter valued at about $723,000. Jane Street Group LLC purchased a new stake in Unum Therapeutics in the third quarter valued at about $150,000. Finally, Vanguard Group Inc. raised its stake in Unum Therapeutics by 4.2% in the third quarter. Vanguard Group Inc. now owns 552,380 shares of the company’s stock valued at $5,690,000 after buying an additional 22,510 shares during the last quarter. 47.46% of the stock is owned by hedge funds and other institutional investors.
UMRX stock traded up $0.04 during trading on Thursday, hitting $3.60. 63,569 shares of the company traded hands, compared to its average volume of 86,913. Unum Therapeutics has a 1 year low of $3.30 and a 1 year high of $17.66.
Unum Therapeutics Company Profile
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.
See Also: What is a Reverse Stock Split?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.